Compare D R Horton Inc (DHI) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Inovio Pharmaceuticals Inc — how do they compare? D R Horton Inc trades at $134.57 (market cap $37.99B), while Inovio Pharmaceuticals Inc trades at $1.11 (market cap $112.19M). The key difference: D R Horton Inc is far larger — about 338.6× Inovio Pharmaceuticals Inc's market cap, and D R Horton Inc pays a 1.33% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DHI | INO | |
|---|---|---|
Market Cap | $37.99B | $112.19M |
Volume | 2,974,460 | 3,201,278 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $2.65 |
52-Week Low | $132.53 | $0.66 |
Typical Hold Time | 46 Days | 43 Days |
Enterprise Value | $43.09B | $83.51M |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $134.49, down 0.91% on the day amid broader housing sector weakness. The stock shows bearish technical signals with resistance at $137 and support at $133. Fundamentally, the company maintains solid profitability with 9.15% net margin and 12.75% ROE, though revenue declined to $34.25B in 2025. Recent earnings beats and a $0.45 dividend declaration provide some positive catalysts despite macroeconomic headwinds affecting homebuilders.
DHI presents a mixed outlook with attractive valuation (P/E 12.95) and strong analyst support (47% buy ratings, $156.57 target) offset by housing market risks. Rising mortgage rates and inflation concerns create near-term pressure, but the company's consistent earnings performance and buyback capacity offer long-term value. Investors should weigh the discounted valuation against sector-specific macroeconomic challenges.
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
